Table 4 Changes in metabolic tumor activity for the VOI_man during the neoadjuvant treatment between the serial ¹⁸F-FDG PET-CT scans

SUV_max

− 2.6 (− 6.4 to − 0.5)^#

− 37.7 (− 67.7 to − 16.4)

− 0.3 (− 0.5 to − 0.1)

− 13.6 (− 17.5 to − 4.7)

− 3.2 (− 6.7 to − 0.5)^#

− 41.6 (− 73.5 to − 27.7)

SUV_peak

−2.8 (− 5.6 to − 0.4)^#

− 45.8 (− 67.4 to − 17.3)

− 0.2 (− 0.5 to 0.0)

− 9.3 (− 16.8 to 0.4)

− 2.9 (− 5.9 to − 0.3)^#

− 45.1 (− 74.4 to − 21.9)

SUV_mean

− 0.9 (− 1.9 to − 0.1)^#

− 39.3 (− 52.0 to − 13.2)

− 0.1 (− 0.2 to 0.0)

− 4.6 (− 17.2 to 2.3)

− 1.0 (− 2.3 to − 0.2)^#

− 44.1 (− 57.2 to − 17.0)

TLG

− 233.6 (− 637.9 to − 28.0)*

− 52.6 (− 73.6 to − 36.3)

− 18.4 (− 57.0 to − 10.6)^#

− 16.3 (− 59.7 to − 5.5)

− 285.0 (− 714.7 to − 34.4)*

− 67.5 (− 82.6 to − 38.2)

MATV (ml)

− 22.1 (− 48.2 to 33.5)

− 7.5 (− 44.9 to 23.5)

− 13.2 (− 53.0 to − 5.3)^#

− 19.8 (− 49.4 to − 2.7)

− 25.4 (− 70.6 to 27.6)

− 31.2 (− 67.2 to 3.8)